High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

PHASE4RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

August 15, 2026

Study Completion Date

August 15, 2027

Conditions
Diabetic Macular Edema (DME)
Interventions
DRUG

Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.

Trial Locations (1)

92835

RECRUITING

Retina Consultants of Orange County, Fullerton

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Retina Consultants of Orange County

OTHER